Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

Shailaja Raj MD; Gregory Springett MD PhD, Daniel Indelicato MD, Marilyn Bui MD PhD, Anthony Conley MD, Sergio Lavilla-Alonso PhD, Xiuhua Zhao MS, Dungsa Chen PhD, Randy Haysek MD, Ricardo Gonzalez MD, Douglas Letson MD, Steven Eric Finkelstein MD PhD, Alberto Chiappori MD, Dimitry Gabrilovitch MD PhD, Scott J Antonia MD PhD
Published: Wednesday, Feb 21, 2018
Shailaja Raj MD

Shailaja Raj, MD


Purpose: Dendritic cell (DC) vaccines are anticipated as a treatment regimen for the future in the management of solid tumors. Previously we have shown that DC-based vaccines show a consistent immune response, safety, and long-term survival with neoadjuvant radiation.


Tumor heterogeneity, high grade, and larger tumors portend a poor prognosis in soft tissue sarcomas.1,2 In particular chemotherapy, radiation, and surgery, have not succeeded in establishing remission in these patients where comorbidities and older age may be risk factors as well.3,4,5,6,7,8 Therefore, tumor vaccines may be ideal in this population due to their favorable toxicity profile.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication